What SINOGENE does

Sinogene (北京希诺谷生物科技有限公司, Beijing Sinogene Biotechnology Co., Ltd.) is a privately held Chinese animal biotechnology company founded in 2012 in Beijing's Zhongguancun Science Park, operating a proprietary somatic cell cloning and CRISPR/Cas9 gene editing platform. Its core commercial activities span companion animal cloning (dogs and cats), long-term somatic cell cryopreservation at -196°C in liquid nitrogen, pet genetic testing covering 230+ canine and 28+ feline hereditary disease mutations, gene-edited large animal disease models for biomedical research, and equine and pigeon genetic testing. The company was the first in China to commercially clone a dog (Longlong, 2017), the first in China to clone a cat (Garlic, 2019), produced China's first cloned police dog (Kunxun, 2019) and the world's first cloned Arctic wolf (2022), and holds the only commercially operating canine and feline somatic cell cloning capability in the country.

The business model combines high-ticket one-time service revenue from cloning (108,000-380,000 RMB per case, with group-buy promotions as low as 118,000 RMB) and premium genetic testing with recurring subscription-style revenue from multi-year cell preservation plans (9,999-19,000 RMB for 10-year terms), plus B2G contracts for elite working dog cloning with police bureaus and B2B revenue from pharmaceutical and academic customers for gene-edited disease models and preclinical CRO services. Go-to-market is hybrid: a network of 600+ designated partner pet hospitals across China serves as the primary consumer touchpoint and sample collection channel, supplemented by a direct sales hotline, Taobao e-commerce storefront, pet industry exhibitions, and Clone Open Day lab tours in Beijing. Government and academic clients are reached through dedicated B2B/B2G sales, with operational subsidiaries now in Beijing, Jiangsu (Xinyi, opened July 2022, 17,000+ sqm), and Henan (Zhengzhou, opened May 2023), supporting an addressable market spanning individual companion-animal owners, public security agencies, pharmaceutical researchers, and the equine industry.

As of 2023 Sinogene had cloned over 500 animals and built a 100+ employee organization across three operating subsidiaries, with cumulative disclosed funding exceeding US$20 million across rounds led by Renbao Qidi Fund, CCB International's predecessors, and 2024's Series 3 led by CCB International. The company explicitly positions itself as a pet life-cycle management platform whose competitive position rests on proprietary cloning know-how, deep wet-lab talent (including a recognized Zhongguancun postdoctoral station), capital-intensive lab infrastructure, and institutional relationships with the Ministry of Public Security and leading Chinese academic institutions.

Name

SINOGENE

Legal name

北京希诺谷生物科技有限公司

Website

https://sinogene.com.cn

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Sinogene is a Beijing-headquartered animal biotechnology company that operates China's first commercial somatic cell cloning and CRISPR/Cas9 gene-editing platform, serving individual pet owners, police and military working dog programs, and pharmaceutical / academic research clients with pet cloning, cell preservation, genetic testing, and gene-edited disease models.

Ownership category

akta.pro rank

Product category

Animal Cloning & Biotechnology Services

SIC

Services-Commercial Physical & Biological Research (8731), Agricultural Prod-Livestock & Animal Specialties (200)

akta.pro primary industry

Cloning & Advanced Reproductive Technologies Services (AFAEAJAL)

Keywords

• Pet cloning services
• Somatic cell cloning
• Gene editing services
• Pet genetic testing
• Animal cell preservation

Headquarters

HQ city

Changping

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Pet Cloning Services: Core commercial service — cloning of pet dogs and cats using somatic cell nuclear transfer technology. Customers pay upfront fees (38万 RMB for dogs at 2018 pricing) and receive a cloned pet after approximately 10-month process. Includes DNA identity verification by third-party (Nanchang Police Dog Base). Premium pricing with group purchase discounts available periodically.
2. Pet Genetic Testing: DNA-based testing services covering breed composition, hereditary disease screening (230+ canine and 28+ feline mutations), drug sensitivity, parentage testing, and health risk assessment. Sampling done by customers at home using buccal swabs or blood samples. Reports delivered within 2 weeks. Lower price point (starting from 199 RMB for basic tests).
3. Pet Cell/Somatic Cell Preservation: Cryopreservation of pet cells in liquid nitrogen at -196°C for future cloning use. Storage terms available: 1, 3, 5, or 10 years. Pricing tiers: 9,999 RMB for 10-year storage for young healthy pets (promotional price). Customers receive a cell preservation certificate.
4. Working Dog Cloning and Gene Editing Services: B2B service for police, military, and security agencies to clone elite working dogs (search and rescue, drug detection, guide dogs) and create gene-edited disease model dogs for pharmaceutical research. Revenue from government and research institution contracts.
5. Horse Gene Testing and Cloning: Services for equestrian industry including genetic disease testing (22 equine hereditary diseases), speed gene testing, parentage testing, and horse cloning. Partnership with China Horse Association.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

SINOGENE provides commercial pet cloning services for dogs and cats using somatic cell nuclear transfer technology, long-term cryopreservation of pet somatic cells in liquid nitrogen at -196°C for future cloning use, and comprehensive pet genetic testing covering breed identification, hereditary disease screening, and drug sensitivity. The company also develops gene-edited large animal disease models (including atherosclerosis and autism model dogs) for pharmaceutical research and working dog cloning services for police and security agencies. SINOGENE built a proprietary animal gene editing and somatic cell cloning technology platform, making it China's first company with fully self-developed commercial pet cloning technology.

Product overview

SINOGENE operates as a comprehensive animal gene technology platform offering a full lifecycle management service for pet genetic material. The core offerings include pet cloning (dog and cat), cell preservation, and genetic testing services, supported by proprietary gene editing and somatic cell cloning technology platforms. The company has achieved multiple world firsts in animal cloning including the first gene-edited cloned dog (Longlong, 2017), China's first cloned cat (Garlic, 2019), and the world's first cloned Arctic wolf (2022). Pricing for commercial services includes pet cloning at 38万元 for dogs and starting from 10.8万元 for cats, with cell preservation plans starting at 9,999元 for 10 years.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 99.9%+ genetic identity between cloned animal and donor confirmed by third-party DNA testing (Nanchang Police Dog Base)
• +3 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered core and minor.

• Beijing Wildlife Park (北京野生动物园)coreStrategic or Co-development Partner · 19 September 2022Co-hosted the world-first cloned Arctic wolf press conference on September 19, 2022. Signifies collaboration between biotech company and wildlife conservation institution for species diversity protection through cloning technology.
• China Working Dog Management Association (中国工作犬管理协会)coreStrategic or Co-development Partner · 24 September 2019Admitted as group member unit in March 2019. Association operates under Ministry of Public Security. Sinogene aims to collaborate on police dog cloning, working dog cell bank establishment, and breeding research with police dog bases.
• Chongbai Kingdom (宠爱王国)coreStrategic or Co-development Partner · 23 August 2019Signed strategic cooperation agreement August 23, 2019. Jointly established the China Pet Gene Bank. Sinogene brings gene technology; Chongbai Kingdom brings pet big data and digital management systems. Aims to provide full life-cycle management services for pets combining digital and biotech approaches.
• CKU China Kennel Union (中爱联合犬业俱乐部)coreStrategic or Co-development Partner · 1 August 2019FCI's official member in China. Provides authoritative purebred dog management and pedigree standards to support Sinogene's pet gene bank and breeding optimization services.
• Beijing Municipal Public Security Bureau - Police Dog BasecoreStrategic or Co-development Partner · 1 August 2019Police-enterprise collaboration. First collaboration used somatic cell cloning technology to cultivate elite police dogs. Six cloned police dogs born August 2019 formally joined Beijing police force. Project part of 'Precision Breeding Core Technology Research Plan for Police Dogs.'
• Shanghai Pet Industry Association / Pet Hospital LeadersminorChannel Partner/ Reseller/ Distributor · 19 June 2019Shanghai Pet Industry Association delegation visited Sinogene in June 2019 and signed brand promotion strategic agreements with hospital leaders including Yang Qiqing (president), Tang Feng, Wang Lu, and others. Aimed to expand pet cloning and gene testing market in Shanghai region.
• Kunming Police Dog Base (公安部昆明警犬基地)coreStrategic or Co-development Partner · 1 September 2018公安部重点研究计划 project 'Gene-edited Working Dog New Variety Breeding.' Kunming Police Dog Base provides elite功勋犬 'Hua Huangma' for cloning. Kunming dogs are China's only domestically developed working dog breed with independent intellectual property.
• Yunnan Agricultural University (云南农业大学)coreStrategic or Co-development Partner · 1 September 2018Co-researcher in the公安部重点研究计划 for gene-edited police dog breeding, alongside Kunming Police Dog Base and Sinogene.
• Beijing Brain Institute (北京脑重大疾病研究院)coreStrategic or Co-development Partner · 1 January 2018Strategic cooperation established September 2019 with Beijing Brain Institute (affiliated with Capital University of Medical Sciences). Jointly established 'Large Animal Model and Drug Evaluation Center.' Focus on cardiovascular and cerebrovascular disease research using gene-edited cloned dogs.
• China Agricultural University (中国农业大学)coreStrategic or Co-development Partner · 1 January 2018Academic collaboration for talent development and research. Dr. Ma Jinlei, a PhD graduate from CAU, initiated the police dog precision breeding project. CAU students conduct internships at Sinogene labs.
• China Horse Association / China Stud Book CommitteecoreStrategic or Co-development Partner · 1 January 2018Jointly established 'China Horse Association Equine Genetic Testing and Research Laboratory.' Sinogene Gene (Sinogene subsidiary) provides horse gene testing, parentage testing, speed gene testing, and cloning. China Horse Association provides institutional support and CSBS membership.
• Chinese Academy of Sciences - Institute of Genetics and Developmental Biology (中科院遗传与发育生物学研究所)coreStrategic or Co-development Partner · 1 January 2018Established 'Joint Canine Research Laboratory' with the Institute. Provides scientific foundation and research capabilities for gene-edited dog disease models and brain science research initiatives.
• 600+ Partner Pet HospitalscoreChannel Partner/ Reseller/ Distributor · 1 January 2017Over 600 high-end pet hospitals across China serve as Sinogene Pet Cloning Designated Hospitals. They distribute genetic testing, cell preservation, and cloning sampling services. Hospitals benefit from adding innovative biotech services to their portfolios.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Crown Bioscience: Global preclinical CRO specializing in oncology and immuno-oncology animal models and drug discovery services. Comparable to Sinogene's biomedical CRO ambitions but at much larger scale. Acquired by JSR Corporation in 2018. Provides benchmark for scaling preclinical CRO services.
• WuXi AppTec: Global CRO/CDMO giant with significant preclinical animal model and drug development services. Indirectly comparable as Sinogene expands into pharma CRO services through Jiangsu facility - represents the upper bound of where Sinogene could scale if biomedical CRO ambitions succeed.
• Cyagen Biosciences: Leading provider of gene-edited mouse/rat models and cell line products headquartered in China. Overlaps with Sinogene's biomedical CRO and gene-edited disease model business, though focuses on rodent rather than large animal (canine) models. Publicly listed on STAR Market.

Direct peers

• Sooam Biotech: South Korean company founded in 2006 by Hwang Woo-suk, world's first commercial dog cloning company. Direct competitor to Sinogene in pet cloning services, offering dog and cat cloning to global customers. Sinogene is noted as 'second only to Sooam' to commercialize dog cloning globally.
• Viagen Pets: US/Australia-based pet and animal cloning company (subsidiary of ViaGen). Cloned the first commercially cloned pet dog in the US and offers equine cloning services. Direct competitor in the premium pet cloning market with comparable somatic cell nuclear transfer technology.
• Boyalife: Chinese biotechnology company with significant investment in animal cloning technology, including plans for a commercial cloning facility. Domestic Chinese peer competing in the same cloning market as Sinogene, particularly for cattle and premium livestock applications.
• Avantea: Italian biotechnology company specializing in animal cloning and reproductive technologies, including horse and livestock cloning. Comparable to Sinogene in technical approach (somatic cell nuclear transfer) and multi-species capability. Smaller-scale competitor in the European market.

Others

• Plusvital: Irish equine genetics company providing speed gene testing, genetic disease screening, and parentage testing for horses. Direct partner of Sinogene (provides Racing GenePak product), serving the same equine industry customer segment with comparable genetic testing services.
• Beijing Wildlife Park: Strategic partner of Sinogene for the world's first cloned Arctic wolf (2022). Adjacent organization in the endangered species conservation space that provides venue and institutional credibility for Sinogene's conservation cloning initiatives.
• Ripubio / Ringpu Bio: Chinese veterinary pharmaceutical company and Series B+ investor in Sinogene (October 2021). Strategic partner providing veterinary pharma expertise and potentially opening veterinary distribution channels. Indirectly comparable as both operate in the Chinese animal health ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SINOGENE